

Gini F Fleming

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10063343/publications.pdf>

Version: 2024-02-01

42
papers

2,045
citations

394421

19
h-index

302126

39
g-index

42
all docs

42
docs citations

42
times ranked

3328
citing authors

#	ARTICLE	IF	CITATIONS
1	Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide?. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100925.	0.6	3
2	Tumor board presentation of a woman with metastatic, hormone receptorâ€­positive, mismatch repairâ€­deficient endometrial cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 102-111.	329.8	3
3	Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3214-3224.	7.0	10
4	Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	28
5	Healthâ€­related quality of life outcomes for the LEAP studyâ€­”CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. <i>Cancer</i> , 2021, 127, 300-309.	4.1	8
6	Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 841-849.	2.5	25
7	Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. <i>Breast Cancer Research</i> , 2021, 23, 18.	5.0	27
8	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5510-5518.	7.0	23
9	Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, 27-35.	1.2	1
10	Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100837.	0.6	4
11	Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. <i>Gynecologic Oncology</i> , 2020, 158, 531-537.	1.4	8
12	Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 245-255.	3.8	19
13	Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. <i>Breast Cancer Research</i> , 2019, 21, 82.	5.0	35
14	Current recommendations and recent progress in endometrial cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 258-279.	329.8	366
15	Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 357-364.	2.5	15
16	Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3433-3446.	7.0	49
17	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptorâ€­“Engineered T Cells for Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5357-5367.	7.0	70
18	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 309-317.	2.3	12

#	ARTICLE	IF	CITATIONS
19	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 459-467.	1.4	61
20	High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 153-160.	1.4	28
21	Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. <i>Gynecologic Oncology</i> , 2017, 147, 672-677.	1.4	14
22	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.	1.8	23
23	The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years. <i>Frontiers in Oncology</i> , 2016, 6, 63.	2.8	37
24	A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. <i>SpringerPlus</i> , 2016, 5, 947.	1.2	29
25	No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. <i>Journal of Oncology Practice</i> , 2016, 12, e901-e911.	2.5	13
26	Chemotherapy-induced peripheral neuropathy: Current status and progress. <i>Gynecologic Oncology</i> , 2016, 140, 176-183.	1.4	196
27	Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. <i>PLoS ONE</i> , 2016, 11, e0147145.	2.5	41
28	Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report. <i>Frontiers in Oncology</i> , 2015, 5, 169.	2.8	10
29	Adjuvant Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer in Premenopausal Patient: Understanding the Data. <i>Current Breast Cancer Reports</i> , 2015, 7, 183-189.	1.0	0
30	Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2015, 138, 656-662.	1.4	57
31	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. <i>Clinical Cancer Research</i> , 2015, 21, 5092-5099.	7.0	3
32	Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. <i>Oncolmmunology</i> , 2015, 4, e1030561.	4.6	52
33	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1207-1214.	10.7	523
34	The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline. <i>Practical Radiation Oncology</i> , 2014, 4, 137-144.	2.1	151
35	Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1250-1251.	1.5	8
36	Topotecan in the treatment of ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2006, 1, 149-158.	0.4	1

#	ARTICLE	IF	CITATIONS
37	A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. <i>Clinical Cancer Research</i> , 2002, 8, 3718-27.	7.0	36
38	Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 489-494.	2.3	2
39	A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 385-388.	2.3	17
40	Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 84-87.	2.3	23
41	Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. , 1996, 77, 2308-2312.		4
42	Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 226-227.	2.3	10